In a significant move to make cancer treatment more affordable, the National Pharmaceutical Pricing Authority (NPPA) has imposed trade margin caps on 137 anti-cancer drugs, resulting in substantial reductions in the prices of hundreds of medicine formulations. The initiative is expected to generate annual savings of approximately ₹3,540 crore for consumers.
The revised prices came into effect on November 9, following recommendations from an expert committee constituted by the Directorate General of Health Services (DGHS) on October 17, 2026.
Significant Reduction in Medicine Prices
According to the Ministry of Chemicals and Fertilisers, 85 pharmaceutical companies had submitted revised prices for 1,364 anti-cancer formulations covering 121 drugs as of November 8.
The price revisions have delivered considerable relief to consumers:
- 679 brands have reported reductions of more than 50% in their prices.
- The highest reduction in Maximum Retail Price (MRP) has reached 96.45%.
- Estimated annual savings for consumers stand at ₹3,540.38 crore.
The move is expected to ease the financial burden on cancer patients and their families, who often face substantial expenditure on long-term treatment and medication.
NPPA Advises Consumers to Check Revised MRPs
The NPPA, operating under the Department of Pharmaceuticals, has urged consumers to verify the revised Maximum Retail Price printed on medicine packaging before making purchases.
Consumers can also check updated medicine prices through the Pharma Sahi Daam mobile application and the authority’s official website.
The authority has made it clear that chemists, retailers and hospital pharmacies cannot charge consumers more than the revised MRP.
Complaint Mechanism Against Overcharging
To protect consumers from overcharging and other pricing violations, the government has strengthened access to grievance redressal mechanisms.
Consumers can report violations through:
- Pharma Jan Samadhan Portal: For submitting complaints related to medicine pricing and overcharging.
- NPPA Helpline: 1800-111-255.
- Pharma Sahi Daam App: For checking updated medicine prices.
Retailers, pharmacies, hospitals and other medical institutions have also been directed to prominently display the revised price lists at their premises and on their respective websites.
Regulatory Framework and Industry Compliance
The price-control provisions were introduced through notification SO 5690 (E), issued on October 17, 2026, and will remain effective until further orders.
The initiative forms part of the government’s broader strategy to improve access to affordable cancer medicines, particularly through the regulation of trade margins on non-scheduled anti-cancer drugs.
At the same time, pharmaceutical manufacturers will continue to have the option of seeking annual price revisions under Paragraph 20(1) of the Drugs (Prices Control) Order, 2013, subject to compliance with the prescribed 30% trade margin ceiling.
A Major Step Towards Affordable Cancer Care
The decision to regulate trade margins on anti-cancer medicines marks an important step towards making essential cancer treatment more accessible and financially manageable.
With hundreds of brands recording significant price reductions and estimated annual consumer savings exceeding ₹3,540 crore, the initiative is expected to provide meaningful relief to patients across the country.
Effective implementation, transparent pricing and strict monitoring of retail practices will be crucial to ensuring that the benefits of these reductions reach patients directly.